On October 12-13, the BioCon Asia 2023-Advanced Cell & Gene Therapy (ACGT) Conference was held in Singapore. Dr. Dudu Tong, the R&D Director of Leman Biotech, participated in the conference and delivered a presentation titled "Metabolically armed CAR-T cells for treatment of solid tumors."

Leman Biotech Makes Multiple Breakthroughs in IIT Clinical Trial for hematological malignancies: 10 Consecutive Patients Achieve Complete Remission, CAR-T Treatment Dose as Low as 1% of the conventional cell therapies, First Central Nervous Metastasis Patient Achieves Sustained Complete Remission for Over 6 Months.

On September 8-9, 2023, the 7th Immunogene and Cell Therapy Conference (IGC 2023) was held at the Beijing International Convention Center. Dr. Youjia Li, R&D Director of Leman Biotech, was invited to deliver a keynote speech. She shared the latest clinical research progress on metabolically enhanced CAR-T cell therapy, receiving high attention from the participating experts.

Leman Biotech Co., Ltd. (referred to as "Leman Biotech") and Hangzhou Neoantigen Biotechnology Co., Ltd. (referred to as "Hangzhou Neoantigen") have recently entered into a collaboration to explore the potential of Meta 10 technology in the development of personalized neoantigen cancer vaccines.

Recently, Prof. Li Tang and Dr. Yugang Guo, founders of Leman Biotech, were invited to Shanghai Pharmaceuticals Group for a visit and exchange. They also visited the Shanghai Biomedical Frontier Industry Innovation Center and the Shanghai Tumor Cellular Therapy Technology Innovation Center, both of which are under construction. Mr. Min Zuo, the former president of Shanghai Pharmaceuticals and chairman of the Shanghai Biomedical Industry Equity Investment Fund, warmly welcomed the Leman Biotech team and participated in a symposium.

Leman Biotech Co., Ltd. (hereinafter referred to as "Leman Biotech"), an innovative metabolic immunotherapy research and development company, has announced a comprehensive strategic cooperation agreement with Chengdu Ucello Biotechnology Co., Ltd. (hereinafter referred to as " Ucello Therapeutics"). Both companies will actively explore the translational applications of metabolic reprogramming technology (Meta 10) in universal CAR T cells.

Leman Biotech Co., Ltd., a clinical-stage biotechnology company focusing on development, production, and commercialization of innovative metabolic immunotherapies, has entered into a comprehensive strategic cooperation agreement with Nanjing Kati Medical Technology Co. Ltd., a leading biotech company in the development of next-generation CAR-T for solid tumors. The two parties will explore the application and translational capability of metabolic reprogramming technology (Meta 10) in CAR-T therapies with a focus on the treatment of solid tumors, and jointly advance the development of cell therapy industry.

Leman Biotech Co., Ltd. (hereinafter referred to as "Leman Biotech"), a clinical-stage biotechnology company focusing on development, production, and commercialization of innovative metabolic immunotherapies, has signed a comprehensive strategic cooperation agreement with Xiangxue Life Science Technology (Guangdong) Co., Ltd. (hereinafter referred to as "Xiangxue Life Sciences"). The two parties will apply their respective technological advantages to fully explore the combined application of Meta 10 metabolic reprogramming technology and TCR-T cell therapy products in the treatment of solid tumors.